StockData
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. (WHWK) stock

WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.08+0.07 (+2.33%)

Close on Nov 17, 2026Market cap $175.59MP/E –Yield –

Whitehawk Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Whitehawk Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.49M, down 22.5% year over year. For fiscal 2025 it was $90.96M, up 78.3% from the year before. The highest annual figure on record is $90.96M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.96M+78.3%
FY2024Dec 31, 2024$51.03M+4.3%
FY2023Dec 31, 2023$48.93M+49.8%
FY2022Dec 31, 2022$32.66M+66.0%
FY2021Dec 31, 2021$19.67M+31.1%
FY2020Dec 31, 2020$15.01M+17.0%
FY2019Dec 31, 2019$12.82M-28.2%
FY2018Dec 31, 2018$17.85M+47.0%
FY2017Dec 31, 2017$12.15M+6.9%
FY2016Dec 31, 2016$11.37M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.89M-73.6%
Q1 FY2026Mar 31, 2026$17.23M+96.1%
Q4 FY2025Dec 31, 2025$19.02M+32.6%
Q3 FY2025Sep 30, 2025$14.35M+43.5%
Q2 FY2025Jun 30, 2025$48.81M+272.8%
Q1 FY2025Mar 31, 2025$8.79M-35.3%
Q4 FY2024Dec 31, 2024$14.35M+12.4%
Q3 FY2024Sep 30, 2024$10.00M-15.9%
Q2 FY2024Jun 30, 2024$13.09M-1.7%
Q1 FY2024Mar 31, 2024$13.59M+24.1%
Q4 FY2023Dec 31, 2023$12.77M+36.3%
Q3 FY2023Sep 30, 2023$11.89M+35.5%
Q2 FY2023Jun 30, 2023$13.32M+72.3%
Q1 FY2023Mar 31, 2023$10.96M+61.3%
Q4 FY2022Dec 31, 2022$9.37M+29.7%
Q3 FY2022Sep 30, 2022$8.77M+52.5%
Q2 FY2022Jun 30, 2022$7.73M+153.7%
Q1 FY2022Mar 31, 2022$6.79M+86.4%
Q4 FY2021Dec 31, 2021$7.23M+35.7%
Q3 FY2021Sep 30, 2021$5.75M+140.3%
Q2 FY2021Jun 30, 2021$3.05M-14.2%
Q1 FY2021Mar 31, 2021$3.64M+99.2%
Q4 FY2020Dec 31, 2020$5.32M+150.0%
Q3 FY2020Sep 30, 2020$2.40M-15.8%
Q2 FY2020Jun 30, 2020$3.55M+56.7%
Q1 FY2020Mar 31, 2020$1.83M-67.3%
Q4 FY2019Dec 31, 2019$2.13M-59.4%
Q3 FY2019Sep 30, 2019$2.84M-34.6%
Q2 FY2019Jun 30, 2019$2.26M-46.5%
Q1 FY2019Mar 31, 2019$5.59M+38.7%
Q4 FY2018Dec 31, 2018$5.25M+38.8%
Q3 FY2018Sep 30, 2018$4.35M+47.7%
Q2 FY2018Jun 30, 2018$4.23M+33.4%
Q1 FY2018Mar 31, 2018$4.03M+78.6%
Q4 FY2017Dec 31, 2017$3.78M+89.7%
Q3 FY2017Sep 30, 2017$2.94M-15.5%
Q2 FY2017Jun 30, 2017$3.17M–
Q1 FY2017Mar 31, 2017$2.26M–
Q4 FY2016Dec 31, 2016$1.99M–
Q3 FY2016Sep 30, 2016$3.48M–

More Whitehawk Therapeutics figures

See a number that looks wrong?